Cargando…

Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients

Detalles Bibliográficos
Autores principales:	Canti, Lorenzo, Ariën, Kevin K., Desombere, Isabelle, Humblet-Baron, Stéphanie, Pannus, Pieter, Heyndrickx, Leo, Henry, Aurélie, Servais, Sophie, Willems, Evelyne, Ehx, Grégory, Goriely, Stanislas, Seidel, Laurence, Michiels, Johan, Willems, Betty, Goossens, Maria E., Beguin, Yves, Marchant, Arnaud, Baron, Frédéric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847067/ https://www.ncbi.nlm.nih.gov/pubmed/35172125 http://dx.doi.org/10.1016/j.ccell.2022.02.005

Ejemplares similares

Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients
por: Canti, Lorenzo, et al.
Publicado: (2021)

Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients
por: Baron, Frédéric, et al.
Publicado: (2022)

Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant
por: Ariën, Kevin K., et al.
Publicado: (2022)

Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial
por: Pannus, Pieter, et al.
Publicado: (2022)

Validation of a multicolor staining to monitor (phospho)STAT5 levels in regulatory T-cell subsets
por: Ehx, Grégory, et al.
Publicado: (2015)

Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
por: Servais, Sophie, et al.
Publicado: (2015)

Post-transplant cyclophosphamide prevents xenogeneic graft-versus-host disease while depleting proliferating regulatory T cells
por: Ritacco, Caroline, et al.
Publicado: (2023)

The prior infection with SARS-CoV-2 study (PICOV) in nursing home residents and staff - study protocol description and presentation of preliminary findings on symptoms.
por: Goossens, Maria E., et al.
Publicado: (2021)

Treatment of AML Relapse After Allo-HCT
por: Webster, Jonathan A., et al.
Publicado: (2021)

Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment
por: Peeters, M., et al.
Publicado: (2021)

Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients
por: Kemlin, Delphine, et al.
Publicado: (2023)

Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors
por: Konnova, Angelina, et al.
Publicado: (2022)

How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation
por: Vandenhove, Benoît, et al.
Publicado: (2020)

Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults
por: Pannus, Pieter, et al.
Publicado: (2023)

Current Status and Perspectives of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia
por: Servais, Sophie, et al.
Publicado: (2022)

The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT
por: Shouval, Roni, et al.
Publicado: (2022)

Overall Survival Rate in Allogeneic Stem Cell Transplanted Patients Requiring Intensive Care Can Be Predicted by the Prognostic Index for Critically Ill Allogeneic Transplantation Patients (PICAT) and the Sequential Organ Failure Assessment (SOFA) Scores
por: De Voeght, Adrien, et al.
Publicado: (2022)

Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease
por: Fransolet, Gilles, et al.
Publicado: (2016)

Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice
por: Ehx, Grégory, et al.
Publicado: (2018)

Personalized prediction of overall survival in patients with AML in non‐complete remission undergoing allo‐HCT
por: Hirabayashi, Shigeki, et al.
Publicado: (2021)

Ontogeny of Myeloid Cells
por: De Kleer, Ismé, et al.
Publicado: (2014)

1753. Adherence and Immunogenicity of Early Vaccination in Pediatric Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Recipients
por: Danino, Dana, et al.
Publicado: (2019)

Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study
por: Ito, Ayumu, et al.
Publicado: (2021)

Make Your Cake and Eat It: Refueling of Immune Fitness in AML Post Allo-HCT Using Baking Soda
por: Tonks, Alex
Publicado: (2021)

Association between adenovirus viral load and mortality in pediatric allo-HCT recipients: the multinational AdVance study
por: Zecca, Marco, et al.
Publicado: (2019)

Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering
por: Ye, Yishan, et al.
Publicado: (2022)

Cumulative incidence of subsequent malignancy after allo-HCT conditioned with or without low-dose total body irradiation
por: Nunez, Lina, et al.
Publicado: (2022)

Respiratory Virus (RV) from Broncho Alveolar Lavage (BAL) Prior to Hematopoietic Cell Transplantation (HCT): A Strong Predictor for Allo-Immune Mediated Lung Syndromes (allo-LS)
por: Versluys, Birgitta, et al.
Publicado: (2015)

Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model
por: Grégoire, Céline, et al.
Publicado: (2019)

1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients
por: Debie, Y., et al.
Publicado: (2022)

Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes
por: Steinhardt, M. J., et al.
Publicado: (2020)

1077. Infectious complications after second allogeneic hematopoietic cell transplant (allo-HCT) in adult patients with hematological malignancies
por: Maurer, Stephen, et al.
Publicado: (2020)

Boosting capacity of a fourth dose BNT162b2 in cancer patients
por: Debie, Yana, et al.
Publicado: (2023)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient
por: Michiels, Yves, et al.
Publicado: (2021)

Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay
por: Mariën, Joachim, et al.
Publicado: (2021)

Abstract 2 Results of an Open Label Expanded Access Study of Omidubicel-onlv for Allogeneic Transplantation (allo-HCT) in Patients with Hematologic Malignancies
por: Horwitz, Mitchell, et al.
Publicado: (2023)

Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease
por: Belle, Ludovic, et al.
Publicado: (2016)

P1318: THE IMPACT OF MELPHALAN DOSING IN COMBINATION WITH FLUDARABINE IN CLINICAL OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES RECEIVING ALLO-HCT
por: Albanyan, O., et al.
Publicado: (2022)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ld2pdobteb0o9tihmekdkjd567